Related Experiment Video
Updated: Mar 26, 2026
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis
Tao Yang1, Hui Yao2, Guangchun He2
11. National Engineering Laboratory for Rice and Byproduct Deep Processing, Central South University of Forestry and Technology, Changsha, Hunan 410004, China;
Abstract:
Despite the tremendous improvement in cancer therapeutics, treatment of late-stage breast cancer remains a challenge for both basic scientists and clinicians. Lovastatin, a natural product derived from Aspergillus terreus or Monascus ruber, has been widely used as cholesterol-lowing drug in the clinic. It also has anti-cancer properties through poorly defined molecular mechanisms. In the present study, we employed a novel antibody microarray technology to investigate the molecular mechanisms through which lovastatin inhibits breast cancer. We found that lovastatin up-regulated 17 proteins and down-regulated 20 proteins in MDA-MB-231 breast cancer cells. These included proteins that modulate apoptosis, cell proliferation, differentiation, signal transduction, epithelial-to-mesenchymal transition and tumor metastasis. Modulation of these pathways may mediate, in part, the inhibitory activity of lovastatin on breast cancer.
Insights
Lovastatin, a cholesterol-lowering drug, shows anti-cancer effects by altering proteins involved in cell death, growth, and metastasis in breast cancer cells.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Late-stage breast cancer treatment remains a significant clinical challenge.
- Lovastatin, a statin drug, possesses known cholesterol-lowering effects and potential anti-cancer properties.
- The precise molecular mechanisms underlying lovastatin's anti-cancer activity are not fully understood.
Purpose of the Study:
- To investigate the molecular mechanisms by which lovastatin inhibits breast cancer growth and metastasis.
- To identify specific protein targets modulated by lovastatin in breast cancer cells.
Main Methods:
- Utilized a novel antibody microarray technology to profile protein expression changes.
- Analyzed protein expression in MDA-MB-231 breast cancer cells treated with lovastatin.
Main Results:
- Lovastatin significantly altered the expression of 37 proteins in MDA-MB-231 cells.
- Identified 17 proteins upregulated and 20 proteins downregulated by lovastatin treatment.
- Affected proteins are involved in critical cellular processes including apoptosis, proliferation, signal transduction, and epithelial-to-mesenchymal transition (EMT).
Conclusions:
- Lovastatin modulates multiple protein pathways crucial for breast cancer progression.
- These protein modulations, including those affecting apoptosis, proliferation, and EMT, likely contribute to lovastatin's inhibitory effects on breast cancer.
